OrganiGram Holdings
Market Cap
CA$888.7m
Last Updated
2021/05/06 23:47 UTC
Data Sources
Company Financials +
Executive Summary
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. More Details
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has OrganiGram Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OGI is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: OGI's weekly volatility has increased from 18% to 25% over the past year.
Market Performance
7 Day Return
-10.5%
OGI
-0.3%
CA Pharmaceuticals
0.8%
CA Market
1 Year Return
45.4%
OGI
100.4%
CA Pharmaceuticals
37.1%
CA Market
Return vs Industry: OGI underperformed the Canadian Pharmaceuticals industry which returned 103.1% over the past year.
Return vs Market: OGI exceeded the Canadian Market which returned 37.1% over the past year.
Shareholder returns
| OGI | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.5% | -0.3% | 0.8% |
| 30 Day | -28.0% | -8.8% | 1.4% |
| 90 Day | 0% | -22.3% | 7.6% |
| 1 Year | 45.4%45.4% | 100.4%100.4% | 41.5%37.1% |
| 3 Year | -33.0%-33.0% | -54.5%-55.2% | 29.5%17.1% |
| 5 Year | 161.4%161.4% | 266.1%263.5% | 58.9%35.1% |
Long-Term Price Volatility Vs. Market
How volatile is OrganiGram Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
OrganiGram Holdings Inc. (TSE:OGI) Analysts Are Reducing Their Forecasts For This Year2 months ago | Simply Wall St
What Did OrganiGram Holdings' (TSE:OGI) CEO Take Home Last Year?3 months ago | Simply Wall St
Analysts Are More Bearish On OrganiGram Holdings Inc. (TSE:OGI) Than They Used To BeValuation
Is OrganiGram Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OGI (CA$2.98) is trading below our estimate of fair value (CA$16.16)
Significantly Below Fair Value: OGI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OGI is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: OGI is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OGI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OGI is good value based on its PB Ratio (2.6x) compared to the CA Pharmaceuticals industry average (2.8x).
Future Growth
How is OrganiGram Holdings forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
67.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OGI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: OGI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OGI's is expected to become profitable in the next 3 years.
Revenue vs Market: OGI's revenue (34.5% per year) is forecast to grow faster than the Canadian market (7.3% per year).
High Growth Revenue: OGI's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OGI's Return on Equity is forecast to be high in 3 years time
Past Performance
How has OrganiGram Holdings performed over the past 5 years?
-67.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OGI is currently unprofitable.
Growing Profit Margin: OGI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OGI is unprofitable, and losses have increased over the past 5 years at a rate of 67.9% per year.
Accelerating Growth: Unable to compare OGI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OGI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: OGI has a negative Return on Equity (-85.76%), as it is currently unprofitable.
Financial Health
How is OrganiGram Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: OGI's short term assets (CA$132.3M) exceed its short term liabilities (CA$19.9M).
Long Term Liabilities: OGI's short term assets (CA$132.3M) exceed its long term liabilities (CA$105.7M).
Debt to Equity History and Analysis
Debt Level: OGI's debt to equity ratio (22%) is considered satisfactory.
Reducing Debt: OGI's debt to equity ratio has reduced from 68.1% to 22% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OGI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OGI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is OrganiGram Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OGI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OGI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OGI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OGI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OGI's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Greg Engel (55 yo)
4.17yrs
Tenure
CA$722,842
Compensation
Mr. Gregory Engel, also known as Greg, has been Director of Canadian Chamber Of Commerce since October 2020. Mr. Engel has been Chief Executive Officer of OrganiGram Holdings Inc. since March 13, 2017. Mr....
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD592.71K) is below average for companies of similar size in the Canadian market ($USD1.21M).
Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: OGI's management team is considered experienced (2.9 years average tenure).
Board Members
Experienced Board: OGI's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.3%.
Top Shareholders
Company Information
OrganiGram Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OrganiGram Holdings Inc.
- Ticker: OGI
- Exchange: TSX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$888.731m
- Shares outstanding: 298.23m
- Website: https://www.organigram.ca
Number of Employees
Location
- OrganiGram Holdings Inc.
- 35 English Drive
- Moncton
- New Brunswick
- E1E 3X3
- Canada
Listings
Biography
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabi...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/06 23:47 |
| End of Day Share Price | 2021/05/06 00:00 |
| Earnings | 2021/02/28 |
| Annual Earnings | 2020/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.